Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials.
OSA is a prevalent sleep-disordered breathing with potentially serious long-term effects, that is most common in people who are overweight and affects millions of people in the US. It results in repeated interruptions in breathing during sleep caused by narrowing and collapse of the airway.
